EndoPulse System for Endoscopic Ultrasound-Guided Therapy of Pancreatic Carcinoma

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$2,206,990.00
Award Year:
2012
Program:
SBIR
Phase:
Phase II
Contract:
2R44CA150484-02
Agency Tracking Number:
R44CA150484
Solicitation Year:
2012
Solicitation Topic Code:
NCI
Solicitation Number:
PA11-096
Small Business Information
BIOELECTROMED CORPORATION
849 MITTEN RD, STE 104, BURLINGAME, CA, -
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
64678464
Principal Investigator:
RICHARD NUCCITELLI
(650) 393-9507
RICH@BIOELECTROMED.COM
Business Contact:
RICHARD NUCCITELLI
(650) 697-3939
RICH@BIOELECTROMED.COM
Research Institution:
Stub




Abstract
DESCRIPTION (provided by applicant): BioElectroMed is developing a new medical device called the EndoPulse that works in conjunction with an echoendoscope to deliver nanosecond pulsed electric field therapy to treat pancreatic carcinoma as well as lesions in the kidney and liver. The EndoPulse is designed to penetrate through the stomach wall into a pancreatic carcinoma before extending an electrode array on both sides of the tumor. We are also developing a high voltage model of the PulseCure nanosecond pulse generator that can generate 30 kV/cm between the two electrode arrays, exposing the entire tumor to this field strength. We have determined that the application of 500 pulses 100 ns long and 30 kV/cm in amplitude triggers apoptosis in all the human tumor cells between the electrodes and causes them to self-destruct within two weeks. We propose to complete the design and testing of both the EndoPulse and PulseCure prototypes and have the final versions manufactured under GMP for use in human clinical trials. These two instruments will then be used to ablate small regions of pancreas in pigs to demonstrate safety and efficacy prior to submitting the application to the FDA for an Investigational Device Exemption (IDE) required for the clinical trial. Once the IDE is granted, we will conduct a six-patient feasibility clinical trial at Stanford University Medical Center with Drs. Ann Chen and Subhas Banerjee acting as Co-Principal Investigators of this trial. These two gastroenterologists receive 3-4patients per month with non-resectable pancreatic carcinomas for which there is currently no effective therapy. If the PulseCure -EndoPulse system can reliably ablate pancreatic carcinomas, it would offer the first effective, non-surgical therapy for pancreatic cancer that could extend the lives of tens of thousands of patients each year. PUBLIC HEALTH RELEVANCE: This research will develop a breakthrough, minimally invasive approach to the treatment of pancreatic tumors for which current treatment options are poor and costly. This new medical device called the EndoPulse is readily extendable to treat other focal internal lesions especially in the liver, kidney and lymph nodes. The EndoPulse is guided to the internal tumor by ultrasound imaging inan echoendoscope and applies ultrashort electrical pulses that cause the tumor cells to self-destruct.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government